Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Ado-trastuzumab emtansine Alectinib Antibody-drug conjugate (DMUC4064A, RG7882) Antibody-drug conjugate (RG7986) Anti-CD20/CD3 TCB (RG6026) Anti-CD20/CD3 TDB (BTCT4465A, RG7828) Anti-CD40 MAb (RG7876) Anti-CEA CD3 TCB (RG7802) Anti–FAP-IL2v FP (RG7461) Anti-OX40 MAb (MOXR0916, RG7888) Anti-TIGIT (MTIG7192A, RG6058) Atezolizumab BET inhibitor (TEN-010, RG6146) Bevacizumab Capecitabine Cergutuzumab amunaleukin (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib Codrituzumab (glypican-3 Mab) (GC33, RG7686) Emactuzumab (RG7155) Erlotinib FAP-DR5 biMAb (RG7386) HIF1 alpha LNA (RO7070179, RG6061) Idasanutlin (RG7388) Ipatasertib (GDC-0068, RG7440) LSD1 inhibitor (RG6016) Navoximod (GDC-0919, RG6078) Obinutuzumab Other Pertuzumab (RG1273) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (RG7596) Rituximab Selective estrogen receptor degrader (SERD[2]) (GDC-0927/SRN-927/RG6047) Taselisib (GDC-0032, RG7604) Vanucizumab (RG7221) Vemurafenib Venetoclax (ABT-199/GDC-0199, RG7601) Vismodegib

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: xxx

Phase: xxx

Region: xxx

Molecule: xxx

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab CA NCT02935361—Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Hematology II, I Atezolizumab CA
NCT02935361—Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) CA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) CA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) CA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) CA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) CO NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) CO
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) FR NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) FR
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) IT NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) IT
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) MA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) MA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) NC NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) NC
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) NY NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) NY
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) TX NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib, Idasanutlin (RG7388), Venetoclax (ABT-199/GDC-0199, RG7601) TX
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab AU NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab AU
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab AZ NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab AZ
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab DE NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab DE
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab KR NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab KR
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab KY NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab KY
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab MN NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab MN
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab NC NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab NC
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab NZ NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab NZ
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab PA NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab PA
NCT02624986—A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AU NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AU
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) DE NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) DE
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) KR NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) KR
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) KY NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) KY
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NZ NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NZ
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) WA NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (RG7388), Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) WA
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AT NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AT
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AU NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AU
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CA NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CA
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CA NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CA
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CO NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CO
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CZ NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CZ
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) ES NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) ES
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) FL NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) FL
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) FR NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) FR
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) HU NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) HU
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) IT NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) IT
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) MO NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) MO
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NJ NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NJ
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NL NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NL
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NM NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NM
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NY NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NY
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) OH NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) OH
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) TN NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Hematology II, I Obinutuzumab, Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) TN
NCT02055820—A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Ado-trastuzumab emtansine, Atezolizumab CO NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Hematology I Ado-trastuzumab emtansine, Atezolizumab CO
NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Ado-trastuzumab emtansine, Atezolizumab MI NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Hematology I Ado-trastuzumab emtansine, Atezolizumab MI
NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab CA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab CA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab CA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab CA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab CT NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab CT
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab KR NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab KR
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab MO NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab MO
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab NY NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab NY
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab TN NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Anti-CD20/CD3 TDB (BTCT4465A, RG7828), Atezolizumab TN
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab CA NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab CA
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab CO NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab CO
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab CT NCT02784483—Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Hematology I Atezolizumab CT
NCT02784483—Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab KS NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab KS
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab NY NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab NY
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab OH NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab OH
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab TN NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab TN
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab TX NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab TX
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab WA NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hematology I Atezolizumab WA
NCT02508870—A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab DE NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab DE
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab FL NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab FL
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab NY NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab NY
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab PL NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab PL
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab WA NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab WA
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab WV NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Atezolizumab, Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab WV
NCT02729896—A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AU NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AU
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AZ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) AZ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) CT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) FL NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) FL
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) GA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) GA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) IT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) IT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) KY NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) KY
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) MI NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) MI
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NJ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) NJ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) PA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) PA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) TX NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (RG7596), Rituximab, Venetoclax (ABT-199/GDC-0199, RG7601) TX
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) AU NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) AU
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) CA NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) CA
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) CO NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) CO
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) DE NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) DE
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) FR NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) FR
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) GA NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) GA
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) IL NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) IL
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) MA NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) MA
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) MD NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) MD
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) NC NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) NC
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) NY NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) NY
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) TX NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) TX
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) WA NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Hematology I Venetoclax (ABT-199/GDC-0199, RG7601) WA
NCT02203773—Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab ES NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Solid Tumor II, I Atezolizumab ES
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab FL NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Solid Tumor II, I Atezolizumab FL
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab GA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Solid Tumor II, I Atezolizumab GA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Atezolizumab TN NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Solid Tumor II, I Atezolizumab TN
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Ado-trastuzumab emtansine, Atezolizumab CO NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Solid Tumor I Ado-trastuzumab emtansine, Atezolizumab CO
NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Tumor
Type
Phase Molecule* Location
Solid Tumor I Ado-trastuzumab emtansine, Atezolizumab MI NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Solid Tumor I Ado-trastuzumab emtansine, Atezolizumab MI
NCT03013218—A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) BE NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) BE
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) FR NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) FR
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) NY NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) NY
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) CA NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) CA
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) DK NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) DK
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) ES NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) ES
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802) CT NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802) CT
NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802) ES NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802) ES
NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802) MA NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802) MA
NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802) NL NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802) NL
NCT02324257—A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab CT NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab CT
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab ES NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab ES
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab FR NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab FR
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab MA NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab MA
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab NC NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab NC
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab NL NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab NL
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab NY NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Solid Tumor I Anti-CEA CD3 TCB (RG7802), Atezolizumab NY
NCT02650713—A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab AU NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab AU
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab AZ NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab AZ
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab CT NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab CT
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab KR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab KR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab MA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab MA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab NY NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab NY
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab TN NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT (MTIG7192A, RG6058), Atezolizumab TN
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab PA NCT03123055—A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Solid Tumor I Atezolizumab PA
NCT03123055—A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) CT NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) CT
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) DK NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) DK
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) ES NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) ES
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) NL NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) NL
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) NY NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Cergutuzumab amunaleukin (RG7813) NY
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) BE NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) BE
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) CT NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) CT
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) ES NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) ES
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) FR NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) FR
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) MA NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) MA
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) NY NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab, Emactuzumab (RG7155) NY
NCT02323191—A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Vanucizumab (RG7221) BE NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Vanucizumab (RG7221) BE
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Vanucizumab (RG7221) ES NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Vanucizumab (RG7221) ES
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab, Vanucizumab (RG7221) FR NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab, Vanucizumab (RG7221) FR
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I BET inhibitor (TEN-010, RG6146) CT NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Solid Tumor I BET inhibitor (TEN-010, RG6146) CT
NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Tumor
Type
Phase Molecule* Location
Solid Tumor I BET inhibitor (TEN-010, RG6146) MA NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Solid Tumor I BET inhibitor (TEN-010, RG6146) MA
NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Tumor
Type
Phase Molecule* Location
Solid Tumor I BET inhibitor (TEN-010, RG6146) MI NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Solid Tumor I BET inhibitor (TEN-010, RG6146) MI
NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Tumor
Type
Phase Molecule* Location
Solid Tumor I BET inhibitor (TEN-010, RG6146) OH NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Solid Tumor I BET inhibitor (TEN-010, RG6146) OH
NCT01987362—A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-DR5 biMAb (RG7386), RO6874813 ES NCT02558140—A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I FAP-DR5 biMAb (RG7386), RO6874813 ES
NCT02558140—A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-DR5 biMAb (RG7386), RO6874813 FR NCT02558140—A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I FAP-DR5 biMAb (RG7386), RO6874813 FR
NCT02558140—A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I FAP-DR5 biMAb (RG7386), RO6874813 TN NCT02558140—A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I FAP-DR5 biMAb (RG7386), RO6874813 TN
NCT02558140—A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Vemurafenib AU NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Solid Tumor I Vemurafenib AU
NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Tumor
Type
Phase Molecule* Location
Solid Tumor I Vemurafenib IL NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Solid Tumor I Vemurafenib IL
NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Tumor
Type
Phase Molecule* Location
Solid Tumor I Vemurafenib TR NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
Solid Tumor I Vemurafenib TR
NCT01767623—A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
1 of 147 clinical trials
1-4 of 147 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
Results contain non-US trial information only.

Click "OK" if you wish to proceed.
CancelOK